Drug Discovery is obviously expensive but the scientists that actually make the discoveries, make very little money. Yes, they might get a bonus or two but it is nowhere close to what the Vice President of the President of the division will make, who get a decent compensation package with stock options and other bonuses. GSK plans to change all that by rewarding scientists make big bucks in compensation for their efforts.
However, as the people at Xconomy discuss, there are two sides of any decision…they argue that giving such a large bonuses may change the scientists, making them less cooperative as well as making them more liable to take decision based upon the large motivational check.
Read more at the link below and decide for yourself, whether GSK has made the right decision.
